U.S. development phase success rates for drugs with and without biomarkers 2006-2015

This statistic shows the probability of success for new drugs with and without biomarkers in the U.S. through the various stages of development, in the period from January 1, 2006 to December 31, 2015. It was found that while the probability that a new drug without biomarkers makes it from Phase I to approval was only 8.4 percent, those with selection biomarkers had a probability of success of 25.9 percent.

Probability of success for new drugs in the U.S. with and without selection biomarkers by development phase between 2006 and 2015

Without biomarkersWith biomarkers
---
---
---
---
---
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

May 2016

Region

United States

Survey time period

January 1, 2006 to December 31, 2015

Supplementary notes

* NDA - New Drug Application / BLA - Biologic License Application.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Clinical trials"

Further Content: You might find this interesting as well

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.